DHAP (chemotherapy)

DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.

DHAP
Specialtyoncology

[R]-DHAP regimen consists of:

  1. Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
  2. (D)examethasone, a glucocorticoid hormone
  3. (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
  4. (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.

Dosing regimen
DrugDoseModeDays
(R)ituximab375 mg/m2IV infusionDay 0
(D)examethasone40 mgPO qdDays 1-4
(H)igh-dose Ara-C - cytarabine2000 mg/m2IV infusion over 2 hrsDay 2, every 12 hours
(P)latinol (cisplatin)100 mg/m2IV infusion over 24 hrsDay 1

References
  1. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.